Abstract: After a brief summary of our asymmetric total syntheses of A83586C and 4-epi-A83586C, we will go on to describe some of our synthetic work on the monamycins, and our most recent total synthesis studies on the bryostatin antitumor macrolides.
INTRODUCTION
Pharmacologically active complex natural products and their synthetic analogues continue to provide fascinating insights into the mechanisms of many important biological processes, and for this reason, chemical interest in the synthesis of such structures remains high [1] . In this mini-review, we will highlight several total synthesis programs that are currently being carried out in our laboratories, two of which were initiated with important cancer biology goals in mind.
DELINEATING THE ROLE PLAYED BY E2F TRANSCRIPTION FACTOR COMPLEXES IN PROLIFERATIVE DISEASE THROUGH USE OF PROBES BASED ON THE A83586C/GE3 CLASS OF ANTITUMOR ANTIBIOTICS
E2F transcription factors are heterodimeric proteins found in all eukaryotes [2] . They bind to and stimulate the transcription of genes necessary for S-phase entry and cellular proliferation (e.g., DNA-polymerase-α, dihydrofolate reductase, thymidine kinase, cyclins A/E, E2F1, cdc-2). In normal cells, many E2F transcription factors have their biological behavior tightly regulated by reversible complexation with the retinoblastoma protein (pRb). However, in a large number of cancers, the pRbs are deleteri-The hallmark of our synthesis was the highly chemoselective endgame that was implemented. It featured a remarkable "biogenetically modelled" union between two fully elaborated fragments devoid of all protecting group functionality, and afforded a glycal that could readily be coaxed into undergoing a highly chemo-and regioselective hydration reaction at C(30) to install the hemiketal unit found in the natural product. Significantly, this transformation was accomplished without perturbation of other delicate functionality within the target structure. We had long considered that a strategy that completely dispensed with protecting groups at the final stages would be a prerequisite for success in the A83586C venture, given the significant amount of acid-, base-, and nucleophile-sensitive functionality embedded within its skeletal array, and its known susceptibility to oxidation and reduction.
As a direct consequence of our synthesis, the first totally synthetic analogs of the A83586C/GE3 class of antitumor antibiotics were recently made available to biologists, who are now evaluating their effects on E2F transcriptional behavior. It is hoped that probe molecules such as 4-epi-A83586C [8] (Scheme 2) might provide powerful new insights into the detailed mechanistic workings of the various E2F/DP proteins, and allow the identification of important new therapeutic targets for the future treatment of proliferative disease.
DEVELOPMENT OF THE TANDEM ELECTROPHILIC HYDRAZINATION-NUCLEOPHILIC CYCLIZATION REACTION FOR BUILDING FUNCTIONALIZED PIPERAZIC ACID DERIVATIVES; APPLICATIONS TO A FUTURE MONAMYCIN H 1 SYNTHESIS
One of the main synthetic dividends that arose from our work on A83586C was our development of the tandem electrophilic hydrazination/nucleophilic cyclization protocol for building functionalized piperazic acid derivatives in homochiral form [9, 10] . Not only did this advance underpin our success in the A83586C undertaking, it also provided us with the vehicle needed for performing subsequent synthetic work on other antibiotic classes, most notably the monamycin cyclodepsipeptides [11] . In this regard, we recently completed the first enantiospecific total synthesis of (3S,5S)-5-hydroxypiperazic acid and (3R,5S)-5-chloropiperazic acid, through use of this tandem process in the key ring-assembly steps. Both of these molecules are constituents of the most potent and complex member of this family, monamycin H 1 . Our methodological work in this area has thus provided the technology needed for a future total
BRYOSTATINS, PROTEIN KINASE C MODULATION, AND THE BRYOSTATIN SYNTHETIC CHALLENGE
Bryostatin 1 is a novel protein kinase C (PKC)-modulating macrolactone showing exceptional antitumor properties against a range of murine tumors that include P388 lymphocytic leukemia, B16 melanoma, and M5076 reticulum cell sarcoma [13] . On account of these favorable pharmacological effects, bryostatin 1 was recently selected for phase II anticancer trials in humans [14] , and in this capacity has already elicited a number of very favorable antitumor responses, one patient now having been completely cured. Given these encouraging findings, and the fact that bryostatin 1 remains exceedingly scarce in nature, synthetic interest in the bryostatins has continued to grow [15, 16] . Currently, the most sought-after prize in the area is a synthetic route that will completely satisfy all future clinical demand. With this in mind, we took up the bryostatin synthetic challenge some years ago.
Our latest retrosynthetic analysis of bryostatin 1 is summarized in Scheme 5. A "biomimetic" macrolactonization on seco-acid 2 is envisaged for forming the 20-membered macrocycle of the natural product. A Julia olefination is planned for installation of the C(16)-C (17)-(E)-disubstituted olefin, and a Kocienski olefination [17] is envisioned for connecting 5 with 6 (Scheme 6).
It was felt that if we could olefinate a C 2 -symmetrical ketone such as 11, then this could offer substantial synthetic advantages for controlling the remote exocyclic olefin geometry in the bryostatin Bring, particularly if it were combined with an intramolecular Williamson etherification reaction to construct the pyran system, and a Smith-Tietze TBS-dithiane coupling tactic [18] to assemble the target ketone 11 (Scheme 7).
Our retrosynthetic planning for the bryostatin 1 C-ring identified bicyclic lactone 14 as a key intermediate, and proposed the use of a stereospecific Wittig olefination to introduce the exocyclic double bond (Scheme 8). Further unravelling of the bicyclic array in 14 subsequently allowed β-keto ester 15 to be selected; its most logical site for disconnection was across its C(18)-C(19) bond through retroClaisen condensation. The latter operation yielded ester 16, all of whose stereocentres appeared installable through a series of Sharpless catalytic AD reactions on appropriate alkene precursors. With this as background, we will now describe recent progress.
The route developed to the bryostatin B-ring is presented in Scheme 9 [16a] . It commenced with a Smith-Tietze bis-alkylation reaction [18] between 2-lithio-2-TBS-dithiane and the homochiral epoxide 13 [19] , available in one step from commercially available (S)-glycidol. This afforded an intermediary alkoxide which was O-silylated in situ with TBSCl to give the product dithiane 17 in 87% yield. The thioketal unit of 17 was then detached with mercuric perchlorate in aq. THF. Unfortunately, the liberated ketone 11 was an unwilling participant in all relevant Wittig and Peterson olefination processes that we examined. Given these difficulties, an alternative method for the olefination of 11 was sought. After considerable effort, a solution to this problem was eventually found. Ketone 11 was reacted with allylmagnesium bromide to obtain 18, and its double bond oxidatively cleaved. The resulting aldol adduct 19 was then subjected to a β-elimination to obtain 20. 1,2-Reduction of 20 with DIBAL and Odesilylation finally delivered triol 21. The latter was a key intermediate in the pathway we had originally formulated.
We were now faced with the challenging prospect of having to differentiate between two partially masked terminal 1,2-diol units that were in a fairly similar environment. This was accomplished through chemoselective oxidation of the allylic alcohol in 21 with MnO 2 . Initially, this afforded an enal which immediately underwent hemiacetalization and subsequent conversion to the α,β−unsaturated lactone in excellent yield. To complete the diol differentiation process, it was necessary to detach both PMB groups from this product with TFA/anisole [20] , and block the hydroxyl groups of 22 with cyclohexylidene and PMB groups to obtain 23. The lactone unit was then reductively ring-opened under Luche conditions [21] to procure diol 24. The primary alcohol in 24 was now protected as a TBDPS ether, and the cyclohexylidene group chemoselectively removed with 1,3-propanedithiol and catalytic BF 3 .Et 2 O at low temperature [22] . As long as the course of this reaction was carefully monitored by TLC, and due care was paid to keeping the temperature below -10 °C, high yields of the desired triol 26 could be isolated routinely. Regioselective O-mesylation was the next step in the synthesis. It was best accomplished using the mesyl chloride-collidine system of O'Donnell and Burke [23] . We had hoped that the dihydroxymesylate 27 would be directly convertible to 7 by treatment with 2 equiv. of NaH. However, these conditions only afforded the δ-hydroxy epoxide 8 in 80% yield. In order to bring about the desired pyran ring-closure process it proved necessary to treat 8 with cat. camphorsulfonic acid in CH 2 Cl 2 [24] . This furnished pyran 7 in 87% yield as the sole reaction product, completing this completely stereocontrolled route to the bryostatin B-ring (6.34% overall yield from 12).
Turning attention now to the C-ring chemistry that has so far been developed [16b], at first we set about introducing the C(26), the C(25)-and the C(23)-hydroxy stereocenters of the C-ring sub-sector through a Sharpless AD reaction [25] on (E)-1,4-hexadiene with excess AD-mix-β (Scheme 10). While this reaction worked well at installing the C(25) and C(26)-hydroxyls with high stereocontrol, the sec-ond AD process on the terminal alkene proceeded without control, affording an inseparable 1:1 mixture of epimers at the C(23)-position. Given this limitation, we took a step back and focused on the selective dihydroxylation of 28 with a limited quantity of AD-mix-β (0.6 equiv), as described by Sharpless et al. [26] . Typically, this provided the volatile diol 31 in 45-59% yield and 94% ee. Our plan now was to introduce the C(23)-stereocenter through Sharpless asymmetric epoxidation [27] . After blocking the hydroxyls in 31 with TBSCl, the double bond of 32 was oxidatively degraded with cat. OsO 4 and NaIO 4 , and the product aldehyde 33 taken forward to the allylic alcohol 35 by Wittig reaction and DIBAL reduction. The Sharpless AE on 35 proceeded efficiently and rapidly, enriching the optical purity of the product to 96% ee. Regioselective deoxygenation of 36 was next effected with REDAL; this produced the 1,3-diol 37 in good yield. Now we needed to selectively position a PMB group on the C(23)-OH, oxidize the C(21)-hydroxyl to the aldehyde, and implement a Wittig reaction on 40 with Ph 3 P=CHCO 2 Et. All these reactions proceeded satisfactorily and furnished the desired enoate 41 as a single geometrical isomer in 89% overall yield from 39. A Sharpless AD reaction on 41 with AD-mix- β was used to set the C(20)-hydroxyl stereochemistry; it furnished diol 42 as essentially a single diastereoisomer. Protection of this functionality was deemed essential for successful implementation of the Claisen condensation process. Happily, the isopropylidenation and Claisen coupling steps both worked well; the desired β-keto ester 15 being isolated in 81% yield from 42. The next phase of the synthesis was removal of the O-isopropylidene group with acidic methanol, and in situ butyrolactonization upon the C(20)-hydroxyl. We anticipated that the latter process would allow the C(20)-and C(21)-hydroxyl groups to be differentiated, and would set the stage for a tandem Fischer glycosidation [28] at C (19) . Reasoning that installation of an electron-withdrawing ester group at C(20) would probably necessitate us using fairly forcing acidic conditions to bring about the desired glycosidation, we considered it best to replace the two TBS protecting groups of 15 with more acid-stable O-pivaloyl esters. The PMB ether was detached from 44 with DDQ to provide 45. Treatment of compound 45 with methanolic HCl afforded the expected methyl glycoside 46 in 58% yield. A Sharpless oxidation [29] with RuCl 3 /NaIO 4 subsequently provided ketone 47, which reacted with Ph 3 P=CHCO 2 Me to furnish a 1:1 mixture of exocyclic alkenes 14 and 48, which were separated by preparative TLC. Wadsworth-Horner-Emmons conditions with MeO 2 CCH 2 P(O)(OMe) 2 gave similar results. Clearly, the butyrolactone unit was insufficiently bulky to direct the stereochemical course of olefination in favor of the desired product 14. Given this impasse, we elected to investigate the effect of increasing the steric bulk of the ester component in our phosphorus ylide. To our delight, changing the ester alkoxy from OMe to OBu-t improved the stereoselectivity of olefination to 3:1 in favor of the desired isomer 50 (Scheme 11). Given this encouraging result, we are now modifying our synthetic pathway to provide an α-alkoxy ketone with a substantially more bulky protecting group on the C(20)-oxygen (e.g., a TES or TBS or PMB ether). Hopefully, these combined tactics will ultimately allow for the completely stereocontrolled introduction of the C-ring exocyclic olefin. Isomerization tactics might also prove useful here in the event of a mixture still being obtained. All of these studies will be the subject of future reports.
CONCLUSIONS
To summarize, we have accomplished the first total synthesis of the antitumor antibiotic A83586C through use of a novel, highly chemoselective, coupling strategy. Our work on this project has paved the way for the synthesis of novel probe molecules based on the A83586C/GE3 structure. Such molecules might prove useful for delineating the biological functioning of many individual E2F transcription factors, and provide powerful new insights into the events controlling the early stages of mammalian cell cycle. Ultimately, such work could lead to the development of a completely new class of antiproliferative drugs which could have a substantial impact on future cancer treatment and cardiovascular medicine.
Our efforts in the A83586C area have also resulted in the introduction of the tandem electrophilic hydrazination/nucleophilic cyclization protocol for building functionalized piperazic acids, and as a consequence, the prospects for achieving a future synthesis of the monamycins now look substantially enhanced.
Research by our group in the bryostatin field is also now starting to bear fruit. We have devised a fully stereocontrolled asymmetric synthesis of an appropriately protected bryostatin B-ring intermediate through exploitation of a subtle C 2 -symmetry-breaking tactic for the control of exocyclic olefin geometry. We have also shown that it is possible to direct the stereochemical outcome of Wittig olefinations on C(20)-substituted C-ring ketone intermediates through use of sterically bulky ylides such as t-BuO 2 CCH=PPh 3 . Further synthetic work on the bryostatin class will be reported in due course.
